Le Lézard
Classified in: Health, Science and technology
Subject: TRI

Researchers Create a Potential Therapy for Deadly Breast Cancer That Has Few Treatment Options


NEW YORK, Dec. 11, 2019 /PRNewswire-PRWeb/ -- Mount Sinai researchers have designed an innovative experimental therapy that may be able to stop the growth of triple-negative breast cancer, the deadliest type of breast cancer, which has few effective treatment options, according to a study published in Nature Chemical Biology in December.

The therapy is known is MS1943. In a cancer cell line and mouse models, it degraded a protein called EZH2 that drives the growth of triple-negative breast cancer.

Research teams led by Jian Jin, PhD, Director of the Mount Sinai Center for Therapeutics Discovery, and Ramon Parsons, MD, PhD, Director of The Tisch Cancer Institute at Mount Sinai, developed MS1943 as a first-in-class small-molecule agent that selectively degrades EZH2. They also showed that agents that inhibit the enzymatic activity of EZH2 but do not degrade EZH2 did not work in triple-negative breast cancer.

MS1943 effectively reduced EZH2 protein levels in a variety of cancer cell lines, including a triple-negative breast cancer cell line, leading to the death of these triple-negative breast cancer cells.

"Our findings suggest that EZH2 selective degraders such as MS1943 may provide an emerging therapeutic approach for the treatment of triple-negative breast cancer," said Dr. Jin, who is also Co-leader of the Cancer Clinical Investigation Program at The Tisch Cancer Institute, Mount Sinai Professor in Therapeutics Discovery, and Professor of Pharmacological Sciences, and Oncological Sciences, at the Icahn School of Medicine at Mount Sinai. "The EZH2 selective degrader reported in this study is also an invaluable tool to test therapeutic hypotheses in other cancers."

This research was supported in part by the grants R01CA230854 and R01CA218600 from the U.S. National Institutes of Health.

About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest integrated delivery system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai's vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The Health System includes approximately 7,480 primary and specialty care physicians; 11 joint-venture ambulatory surgery centers; more than 410 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools", aligned with a U.S. News & World Report's "Honor Roll" Hospital, No. 12 in the nation for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of top U.S. hospitals; it is one of the nation's top 20 hospitals in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Geriatrics, Gynecology, Nephrology, Neurology/Neurosurgery, and Orthopedics in the 2019-2020 "Best Hospitals" issue. Mount Sinai's Kravis Children's Hospital also is ranked nationally in five out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 12th nationally for Ophthalmology, Mount Sinai St. Lukes and Mount Sinai West are ranked 23rd nationally for Nephrology and 25th for Diabetes/Endocrinology, and Mount Sinai South Nassau is ranked 35th nationally for Urology. Mount Sinai Beth Israel, Mount Sinai St. Luke's, Mount Sinai West, and Mount Sinai South Nassau are ranked regionally.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

 

SOURCE Mount Sinai


These press releases may also interest you

at 16:55
Global design company, West Elm, a portfolio brand of Williams-Sonoma, Inc. , the world's largest digital-first, design-led and sustainable home retailer, announced today the launch of a new mobile iOS design and shopping app. Developed with the...

at 16:35
Today Domo announced at Domopalooza: the AI + Data Conference enhancements to Cloud Amplifier, the company's multi-cloud data offering, to enable users with the powerful and flexible tools they need to fully integrate with multiple cloud data...

at 16:30
Nuvve Holding Corp. (Nuvve) , a green energy technology company that provides a globally-available, commercial vehicle-to-grid (V2G) technology platform designed to enable electric vehicle (EV) batteries to store and resell unused energy back to the...

at 16:28
The Rett Syndrome Research Trust (RSRT) is proud to announce its partnership with PMD Solutions, a leading provider of innovative healthcare technologies, in their upcoming biosensor validation study called VIBRANT. PMD Solutions will generously...

at 16:25
Fortive Corporation ("Fortive") today announced that it will webcast its earnings conference call for the first quarter 2024 on Wednesday, April 24, 2024 beginning at 12:00 p.m. ET and lasting approximately 1 hour. The call and an accompanying...

at 16:20
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31,...



News published on and distributed by: